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ABSTRACT
Herpes zoster (HZ) or “shingles” results from a reactivation of the varicella zoster virus (VZV) acquired
during primary infection (chickenpox) and surviving in the dorsal root ganglia. In about 20% of cases, a
complication occurs, known as post-herpetic neuralgia (PHN). A live attenuated vaccine against VZV is
available for the prevention of HZ and subsequent PHN. The present study aims to update an earlier
evaluation estimating the cost-effectiveness of the HZ vaccine from a Swiss third party payer perspective.
It takes into account updated vaccine prices, a different age cohort, latest clinical data and burden of
illness data. A Markov model was developed to simulate the lifetime consequences of vaccinating 15% of
the Swiss population aged 65–79 y. Information from sentinel data, ofﬁcial statistics and published
literature were used. Endpoints assessed were number of HZ and PHN cases, quality-adjusted life years
(QALYs), costs of hospitalizations, consultations and prescriptions. Based on a vaccine price of CHF 162,
the vaccination strategy accrued additional costs of CHF 17,720,087 and gained 594 QALYs. The
incremental cost-effectiveness ratio (ICER) was CHF 29,814 per QALY gained. Sensitivity analyses showed
that the results were most sensitive to epidemiological inputs, utility values, discount rates, duration of
vaccine efﬁcacy, and vaccine price. Probabilistic sensitivity analyses indicated a more than 99% chance
that the ICER was below 40,000 CHF per QALY. Findings were in line with existing cost-effectiveness
analyses of HZ vaccination. This updated study supports the value of an HZ vaccination strategy targeting
the Swiss population aged 65–79 y.
KEYWORDS
cost-effectiveness; herpes
zoster; post-herpetic
neuralgia; Switzerland;
vaccination
Introduction
Infection with the varicella zoster virus (VZV) primarily causes
chickenpox. It can cause herpes zoster (HZ) or “shingles” in the
later life of persons with a primary infection. HZ causes rash and
(severe) pain. Pain persists for an extended time period after the
cutaneous eruption has healed, in about 25% of cases with post-her-
petic neuralgia (PHN).1 PHN is deﬁned as pain persisting after the
typical cutaneous rash has healed. This is in contrast to pain due to
swelling and inﬂammation when the rash is still persisting and not
due to nerve damage. The time during which painmust persist after
healing for the rash to be classiﬁed as PHN varies between guide-
lines (1 week, 28 days, 3 months). While there is no international
consensus on the deﬁnition of PHN, the most commonly accepted
one is based on a time of 3 months, and this deﬁnition was also
used in this article.2-4 Patients with PHN can develop severe physi-
cal, occupational and social disabilities as a consequence of the
enduring pain,5-7 with a profound impact on daily live.8
Because of age-related decrease in cell-mediated immunity,
the individual lifetime risk of developing HZ increases with
higher age.1,9 The annual incidence of HZ is as high as 10 per
1,000 patient-years in persons over 75 y of age.10 According to
incidence estimates for Switzerland, about 11,000 people older
than 50 y old are affected each year by HZ.11
Due to the fact that almost everyone has had chickenpox as
a child, almost everyone is at risk. However, it is currently not
possible to predict who will develop HZ, ophthalmic zoster and
PHN. There is evidence that the proportion of patients
experiencing PHN increases with age to about 34% in HZ
patients aged 80 years.12
A live attenuated vaccine against varicella zoster virus infec-
tion is available (Zostavax, MERCK & CO., INC) for the pre-
vention of HZ and subsequent PHN. The efﬁcacy of this
vaccine has been tested in 2 randomized studies.4,13,14 Further-
more, retrospective cohort studies have conﬁrmed the effective-
ness under real-life conditions.15,16 The vaccine received a
marketing authorization for immunocompetent individuals
aged 50 y or older by the European Agency for the Evaluation
of Medicinal Products (EMA), and several European countries
recommend and/or fund HZ vaccination, including Austria,
Greece, the UK and France, as well as some regions in Ger-
many, Italy and Spain.17 However, the vaccine has not been
introduced in the Swiss vaccination plan.18,19
An economic evaluation of HZ vaccination in elderly people
aged 70–79 y in the Swiss population was conducted in 2011 by
one of the authors of the present study (TD Szucs) and col-
leagues. Since this economic evaluation was conducted, new
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data on the duration of the vaccine efﬁcacy based on long-term
efﬁcacy data have become available and input parameter values
(demographics, hospitalization costs, coverage and vaccine
price assumptions) have changed.4,20
The present study aims to update the earlier economic eval-
uation of the cost-effectiveness of HZ vaccination from a third
party payer perspective, focusing on the Swiss population aged
65–79 y. We incorporated the latest data or estimates of vaccine
efﬁcacy, demographics, hospitalization costs, coverage rate and
vaccine price.
Results
Base-case analysis on public health and economic impacts
The target population included individuals aged 65 to 79 y
in Switzerland. The vaccination strategy assumed a vaccina-
tion coverage of 15%. Hence, 1,034,026 individuals were
included, whereof 155,104 (15% of the total target popula-
tion) persons were assumed to be vaccinated in the vaccina-
tion strategy. The base case results (Table 1) indicated that
the vaccination of people aged 65–79 years, in comparison
with no vaccination and over a lifetime horizon, would
yield public health beneﬁts in the form of additional QALYs
and HZ and PHN cases avoided, and economic beneﬁts
through a reduced use of health care resources required to
treat HZ and PHN. In the base case, the HZ vaccination
strategy avoided 3,489 HZ cases and 1,244 PHN cases.
QALYs accrued were 12,192,998 and 12,192,394 for the vac-
cination and no vaccination strategies, respectively, implying
a difference of 594 QALYs in favor of the vaccination strat-
egy. The total mean cost was CHF 156,136,484 and CHF
138,416,397 for the vaccination and the no vaccination
strategies, respectively, resulting in additional costs of CHF
17,720,087 for the vaccination strategy. The incremental
cost-effectiveness ratio (ICER) for vaccination of those aged
65–79 was CHF 29,814 per QALY gained.
The number needed to vaccinate (NNV) quantiﬁes the number
of people that needs to be vaccinated to prevent one case of the
disease, and is an indicator of vaccination effectiveness. In the pop-
ulation aged 65–79 years, 44 people would need to be vaccinated
to avoid one case of HZ and 125 people would need to be vacci-
nated to avoid one case of PHN. The cost per HZ case avoided
was estimated at CHF 5,078. On the other hand, the average cost
of avoiding one case of PHN was higher, partially because the
number of incident PHN cases was much lower than for HZ: in
fact, patient had to experience HZ before PHN.
Sensitivity analysis
Deterministic sensitivity analysis
Table 2 illustrates the impact on the ICER resulting from a
series of sensitivity analyses performed for the included popula-
tion. The results were sensitive to several parameters.
Assuming discount rates of 0% or 5% for both costs and
outcomes had a strong impact on the ICER (range: CHF
24,254/QALY to CHF 33,293/QALY). Using alternative util-
ity inputs extracted from other publications had a detrimen-
tal effect on the ICER (Table 2), since these values did not
penalize severe pain states as much as the base case inputs
(range: CHF 36,279/QALY to CHF 42,886/QALY).21-23 On
the contrary, the use of alternative inputs for both HZ and
PHN incidence had a very favorable effect, with resulting
ICERs ranging from CHF 16,997/QALY to CHF 23,189/
QALY.24,25 Assuming a vaccine efﬁcacy duration of 10 y for
both HZ and PHN with no waning had a small impact on
the ICER (CHF 26,978/QALY).
Increasing or decreasing the vaccine price by 10% (CHF
178.20 or CHF 145.80) had a substantial impact on the
ICER (CHF 30,621/QALY or CHF 23,454/QALY, respec-
tively). Increasing healthcare resource use for HZ and PHN
care by 20% resulted in an increased ICER (CHF 29,913/
QALY) whereas decreasing healthcare resource use by 20%
resulted in a decreased ICER (CHF 24,162/QALY). Assum-
ing no hospitalization or using alternative values for hospi-
talization costs ( § 30%) had a limited effect on the cost-
effectiveness results.26 The variation of the vaccine efﬁcacy
( § 10%; consistent with the 95% conﬁdence interval seen
in the clinical trial4) at vaccine uptake led to a variation of
10% of the ICER in both directions.
Probabilistic sensitivity analysis
Figure 1 shows the cost-effectiveness scatter plot resulting from
the PSA, for the outcome of cost per QALY gained. There was
an evident negative correlation between costs and outcomes,
meaning that high effectiveness and lower costs were associ-
ated, and vice versa.
The probability of not surpassing the cost-effectiveness
threshold of CHF 40,000 from a third party payer per-
spective was 99% for the vaccination strategy. The corre-
sponding cost-effectiveness acceptability curve (CEAC)
over a series of thresholds is shown in Appendix 1. The
CEAC represents the probability of the vaccination strat-
egy being cost-effective, over a range of cost-effectiveness
thresholds.
Table 1. Strategy-speciﬁc results and base case ICER.
Population of Switzerland,
aged 65 to 79 years Cost (CHF) QALY HZ cases PHN case
Vaccination coverage 15%
(absolute measure)
155,104 156,136,484 12,192,988 97,657 22,720
No vaccination (absolute measure) 1,034,026 (unvaccinated) 138,416,397 12,192,394 101,146 23,964
Difference — 17,720,087 594 3,489 1,244
ICER (lifetime) — — CHF 29,814/QALY CHF 5,078/HZ
case avoided
CHF 14,246/PHN
case avoided
HZ: herpes zoster; ICER: incremental cost-effectiveness ratio; PHN: indicates post-herpetic neuralgia, deﬁned as pain persisting or occurring respectively at 3 months after
herpes zoster rash onset; QALY: quality-adjusted life-years.
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Discussion
The present cost-effectiveness analysis provides an update of an
earlier economic evaluation of HZ vaccination in Switzerland
in comparison with no vaccination. It is based on new informa-
tion regarding the age group to be targeted and new data on
the duration of vaccine efﬁcacy based on long-term efﬁcacy
data, coverage rate and price. The main results of the present
analysis show that vaccinating persons in Switzerland aged
65–79 y is likely to lead to both substantial clinical and
economic beneﬁts. These beneﬁts include a reduced number of
HZ and PHN cases, an increase in health-related quality of life
(measured as QALYs), in addition to a reduction in hospitaliza-
tions, consultations and prescription costs for the vaccinated
population. These results are explained by the association of
both good vaccine efﬁcacy and a substantial burden of disease
in this age group.
Nevertheless, the costs of the vaccination strategy could not
be fully compensated by the saved costs of treating HZ and
PHN cases. The analysis indicates an ICER of CHF 29,814 per
Table 2. Deterministic sensitivity analysis (lifetime results).
Incremental Cost Incremental QALYs ICER (cost/QALY)
Base Case 17,720,087 CHF 594 29,814 CHF
Discount rates
0% for outcomes and costs 15,804,154 CHF 652 24,254 CHF
5.0% for costs/5.0% for outcomes 10,371,201 CHF 312 33,293 CHF
Epidemiology (in the absence of vaccination)
HZ Incidence (Gauthier25) 9,460,082 CHF 408 23,189 CHF
HZ & PHN Incidence (Edmunds24) 8,306,218 CHF 489 16,997 CHF
HZ pain split (Gauthier25) 10,652,589 CHF 316 33,746 CHF
Management care of HZ
No Hospitalization 10,912,800 CHF 370 29,481 CHF
Michel 200626 10,358,801 CHF 370 27,984 CHF
CHUV¡30% 10,279,696 CHF 370 27,770 CHF
CHUVC30% 9,737,035 CHF 370 26,304 CHF
Vaccine Admin Cost
40.50 CHF 11,629,807 CHF 370 31,418 CHF
57.50 CHF 13,176,637 CHF 370 35,596 CHF
Vaccine Price
178.20 CHF 11,335,000 CHF 370 30,621 CHF
145.80 CHF 8,681,731 CHF 370 23,454 CHF
Utilities
Bala utilities for HZ and PHN22 17,720,087 CHF 443 39,956 CHF
Pellissier utilities for HZ and PHN21 17,720,087 CHF 412 42,886 CHF
Van Hoek utilities for HZ & SPS utilities for PHN23 17,720,087 CHF 461 38,781 CHF
Resource use costs
20% Increase 8,944,040 CHF 370 24,162 CHF
20% Decrease 11,072,691 CHF 370 29,913 CHF
Vaccine efﬁcacy duration and waning rate
C10% VE on both HZ and PHN 17,222,342 CHF 627 27,453 CHF
¡10% VE on both HZ and PHN 18,238,604 CHF 560 32,582 CHF
HZ: lifetime; PHN: 10 years; waning: 8.3% 10,002,866 CHF 376 26,578 CHF
HZ: lifetime; PHN: 10 years; waning: 4.15% 238,934,628 CHF 9544 25,035 CHF
HZ: 10 years; PHN: 10 years; waning: 0% 240,991,187 CHF 8933 26,978 CHF
CHUV: University of Vaud Hospital Centre; HZ: herpes zoster; ICER: incremental cost-effectiveness ratio; PHN: indicates post-herpetic neuralgia, deﬁned as pain persisting
or occurring respectively at 3 months after herpes zoster rash onset; QALY: quality-adjusted life-years.
Figure 1. Cost-effectiveness plane derived from the probabilistic sensitivity analysis (cost/QALY).
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QALY gained, over a lifetime horizon. In Switzerland, there is
no formally accepted cost-effectiveness threshold. The most
frequently cited cost-effectiveness thresholds are from the Brit-
ish National Institute for Health and Clinical Excellence
(NICE) (GBP 20,000 to 30,000 per QALY gained).27 To transfer
these values to Switzerland, they could be put in relation to the
per capita gross domestic product (GDP) per year. For exam-
ple, in 2013 the ratio of the ICER threshold to per capita GDP
was 0.71 in the UK. Applying this value to the Swiss per capita
GDP in 2013 would lead to an ICER threshold in the range of
CHF 40,117 to CHF 60,171 per QALY. The World Health
Organization (WHO) suggests cost-effectiveness thresholds of
2–3 times the GDP per person.28 Considering the 2013 Swiss
GDP per person of CHF 84,748, the WHO recommendation
would yield Swiss thresholds in a range of CHF 169,496 to
CHF 254,244. In the present study, the base-case ICER is well
below the range of discussed thresholds.
Results of this study are very similar to those obtained in the
earlier Swiss analysis by Szucs et al., which assessed the cost-
effectiveness of the HZ vaccine in the Swiss population aged
70–79 y and estimated the ICER at CHF 25,538 per QALY
gained from the third party payer perspective (versus CHF
29,814 per QALY gained in the current study for the 65–79 y
old population).11,29 The present, updated analysis includes the
most recent available data and estimates of vaccine efﬁcacy,
demographics, hospitalization costs, coverage rate and vaccine
price. The most important change related to the assumptions
on vaccine efﬁcacy duration. In the base case analysis by Szcus
et al, the vaccine was assumed to offer lifetime protection
against HZ and PHN.11 Even in the sensitivity analysis, only
annual waning of the achieved protection against HZ of 8.3%
was applied. In contrast, we applied estimates from a recent
durability model for the input of vaccine efﬁcacy, and also used
only 10 y of protection against PHN in the base case
analysis.21,30
In a recent systematic review, the cost-effectiveness of rou-
tine varicella and HZ vaccination was assessed in high-income
countries.31 In total, 15 studies were included which considered
the health economic impact of HZ vaccination exclusively.
From a payer perspective, ICERs ranged from EUR 5,412 to
140,125 per QALY gained. The majority of the studies reported
ICERs between EUR 10,000 to 40,000/QALY, which is in line
with our results. Interestingly, studies which included waning
of vaccine-induced immunity showed a u-shape age-depen-
dence of the cost-effectiveness results (i.e. ICERs decreased
with increasing age up to 60–70 y and then increased further
with increasing age). Furthermore, many studies indicated that
cost-effectiveness results were dependent on the duration of
vaccine-induced protection, the vaccine price and the applied
cost per QALY threshold. Other recent health economic evalu-
ations from Portugal, France and Italy reported favorable cost-
effectiveness results for HZ vaccination among elderly.32-34
Strengths of the present study are the robustness of the
model that was validated through an internal validation with
results exactly matching the trail results, and investigated by
several health authorities (e.g. in the Netherlands35 and
France36). Furthermore, the use of local data sources allowed
producing country-speciﬁc results. This advantageous property
of the model has been attested by the external validation and
led to analyses for several countries (e.g., UK,37 Belgium,38
France,39 Germany,40 Spain41 or Switzerland11).
The results are indeed consistent with the conclusions
drawn by 2 recent literature reviews of existing health economic
evaluations of HZ vaccination among adults over 50 years.42,43
Another strength is the incorporation of the vaccine waning
effect, which dramatically reduces the uncertainty around vac-
cine efﬁcacy duration. Indeed, consideration of vaccine efﬁcacy
waning since the time of vaccination along with the age at vac-
cination is crucial in estimating the cost-effectiveness of HZ
vaccination.44 Whereas the previous version of the model was
using efﬁcacy waning assumptions that were not age speciﬁc
given an absence of follow-up data, in the present analysis, real
life waning in efﬁcacy was taken into account.
This study has several limitations, most of which are related
to the model input parameters. First, the sources used for some
parameters (PHN incidence, utility values, disease severity
split) were not speciﬁc to Switzerland because no Swiss data
were available. However, Swiss speciﬁc references were used as
much as possible and the most uncertain parameters were
extensively assessed in sensitivity analyses. The latter demon-
strated that the conclusions of the study were robust to input
parameters changes since ICERs remained below or close to
CHF 40,000 per QALY gained. Second, resource use and corre-
sponding cost data were taken from a Swiss burden of illness
study based on Swiss expert opinions conducted in 2007 In the
absence of better data, these were inﬂated to represent 2014
costs.26 Sensitivity analysis indicated an only mild impact of
these parameters on the ICER result. Third, hospitalization
costs were assessed using hospitalization records extracted
from only one hospital in Switzerland (CHUV). Thus, hospital-
ization costs may not be representative for the entire Swiss pop-
ulation. Moreover, the same ICD codes were used to assess HZ-
related and PHN-related hospitalizations, and may have led to
a ﬂawed estimation of PHN hospitalization costs (no differenti-
ation was possible). It is also possible that following a diagnosis
of HZ or PHN, hospitalizations were not coded as being speciﬁ-
cally for HZ or PHN, and could therefore not be considered.
This implies a possibility that the estimated costs were under or
over-estimated. However, since an underestimation of costs
favors the vaccine arm this limitation makes the results more
conservative.
The percentage of elderly people in Switzerland increases.
The Swiss Federal Ofﬁce of Statistics estimated that by 2045,
the percentage of residents over the age of 65 may reach 27.4%
of total population.45 People are living longer but are experienc-
ing more chronic and infectious diseases as they age.46 Inves-
ting in the health of the senior population, including the
prevention of disease, is important in light of this demographic
change and ultimately to preserve healthcare system
sustainability.47,48
In summary, health economic evidence provided by this
study supports the value of an HZ vaccination strategy target-
ing the Swiss population aged from 65 to 79 y. Comprehensive
sensitivity analyses demonstrated that results are robust and
aligned with existing cost-effectiveness analyses of HZ vaccina-
tion.42,43 With the elderly population in Switzerland steadily
growing in size, the number of patients presenting with HZ is
also likely to increase and this will place a greater burden on
1498 P. R. BLANK ET AL.
D
ow
nl
oa
de
d 
by
 [U
ZH
 H
au
ptb
ibl
iot
he
k /
 Z
en
tra
lbi
bli
oth
ek
 Z
ür
ich
] a
t 1
3:4
3 0
2 J
an
ua
ry
 20
18
 
the healthcare systems. No preventative or curative treatment
of HZ exists. A cost-effective prevention strategy by vaccination
which was demonstrated to be may offer a good option for the
future.
Materials and methods
Overview of the model
The model simulates the lifetime incidence and consequences
of HZ in the Swiss population aged 65–79 y at the time of vacci-
nation based on earlier publications.11,37 Two strategies are
compared: the adoption of a vaccination strategy in Switzer-
land, for which a 15% vaccine coverage rate is assumed to be
achieved in the relevant age group, and the current Swiss policy
of no vaccination (not taking into account vaccination paid by
customers). It comprises 4 different health states including
healthy (no HZ symptoms); HZ; PHN; and death. The HZ and
PHN health states are further divided into different pain sever-
ity levels. Recurrent HZ and subsequent neuropathic pain are
also allowed states, but are constrained to a one-time-only
recurrent episode (Fig. 2). It was assumed that there was no
additional recurrent HZ episode.
The model uses a Markov cycle length of one month. Within
each cycle, members of the cohort can remain in their current
health state or make a transition into one of the allowable
states. Transitions are governed by a matrix of probability val-
ues. The transition probabilities determine the proportion of
the cohort moving through the HZ and PHN states, and even-
tually to death, in each monthly cycle. The model runs until the
entire cohort has died.
For most epidemiological and cost parameters, age-speciﬁc
Swiss data were retrieved. HZ-related transition probabilities
were derived from published literature. Costs were assessed from
a third party payer perspective. Discount rates applied in the
base case were 3.5% for costs and for 1.5% for outcomes,49,50 to
maintain comparability with the previous analysis.11 The model
was developed in Microsoft Excel, with additional program-
ming in Visual Basic for Applications (VBA). We updated the
earlier analysis by Szucs et al.11 by incorporating the latest data
or estimates of vaccine efﬁcacy duration, demographics, hospital-
ization costs, coverage rate and vaccine price.
Model input parameters
Demographic data
The population was analyzed as separate 5-year age cohorts
(65–69 years, 70–74 years, and 75–79 years). Results were sub-
sequently combined. The Swiss population size and monthly
mortality rates (Table 3) were obtained from the Swiss Federal
Statistical Ofﬁce.51,52 In total, 1,034,026 individuals were
included in the model, representing the population aged
65–79 y.
Epidemiology of herpes zoster
Herpes zoster. Data from the Swiss Sentinel Surveillance Net-
work were used as a source of data for HZ incidence rates
(Table 3).53 For HZ duration, information from a clinical trial
was used.4 Most patients experienced a duration of 30 days, as
also reported elsewhere in the literature.4,54,55
Figure 2. Overview of model health states.
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Evidence from the UK indicates no mortality directly linked
to HZ.25 As no information on HZ mortality was available for
Switzerland, the UK data was applied in the model and HZ
mortality was set at 0% for all age groups.
Post-herpetic neuralgia. The proportion of PHN has been
reported as a proportion of HZ patients who develop PHN,
and has been applied only to those HZ cases presenting with
pain (Table 3).25 The literature provides evidence that patients
have a higher risk of developing PHN if they experience severe
pain during HZ. To reﬂect the increased (decreased) odds of
developing PHN by patients having a severe (mild) HZ pain
episode relative to moderate HZ pain, odds ratios of 2.39 for
severe pain and 0.88 for mild pain, obtained from the literature,
were applied.55 Hence, patients with severe pain were estimated
to be 2.8 times more likely to develop PHN than patients with
lower levels of pain or no pain.
Neuropathic pain following recurrent HZ was assumed to
occur as frequently as the same proportions as ﬁrst time PHN.
No mortality was deemed to be associated with PHN. In the
absence of literature on the subject, this was conﬁrmed by
expert opinion.
Furthermore, the duration of PHN is reduced through vacci-
nation, and this ultimately affects the pain severity experienced
by the patients, as they spend a shorter period of time in each
painful PHN health state (Table 3). Reported pain splits by age
group are shown in Table 3
HZ and PHN pain split
It was important to model the split between the different pain
states for HZ and PHN as these were linked to PHN probability
and treatment costs. The pain split results from Oxman et al.
were used in the base case analysis.4 In this trial, pain duration
and severity were measured using the HZ severity-of-illness
score (HZSOI) and Zoster Brief Pain Inventory (ZBPI). Pain
split data were reported as proportions of patients with no,
mild, moderate or severe pain, and were investigated at study
recruitment (Table 3).
Data for gender split in HZ and PHN cases were avail-
able from Gauthier et al. reporting a proportion of women
of 61.10% in all HZ cases and of 65.4% in all PHN cases.25
This information was incorporated in the model where
gender speciﬁc values were relevant (e.g., for utility
decrements).
Vaccine efﬁcacy
Reduction of HZ incidence and PHN proportion. Vaccine efﬁ-
cacy was derived from clinical trials.4,20 The reduction in the
number of PHN cases is due to the indirect reduction in the
HZ cases. The vaccine efﬁcacy data on HZ and PHN cases are
expressed as relative risks and differ by age group (Table 3).4,20
In scenario analyses, alternative inputs for both HZ and
PHN incidence were tested.24,25
PHN duration. In addition, vaccination has a positive effect on
the duration of PHN. In the model this indirectly impacted the
pain severity experienced by the patient since it implied a
shorter period of time spent in each painful PHN health state.
Within the vaccination group, the PHN duration was assumed
to be 8.07 months and 9.58 months for the 60–69 y and the
70C years old individuals, respectively. Unvaccinated individu-
als experienced a longer PHN duration of 10.34 months and
12.90 months for the 60–69 y and the 70C years old individu-
als, respectively (Table 3)4,56.
Vaccine efﬁcacy duration and waning rate for HZ. The HZ
vaccine efﬁcacy was assumed to decrease over time. Available
Table 3. Input parameters related to HZ/PHN vaccine and epidemiology.
65–69 years 70–74 years 75–79 years Source
Population
Population size 427,426 341,072 265,528 51
General mortality rate (Switzerland, 2013) 0.1% 0.17% 0.29% 52
HZ
HZ incidence (annual) 0.41% 0.60% 0.60% 53
HZ pain split
No pain 27% 26% 26% 4
Mild pain 41% 32% 32% 4
Moderate pain 18% 23% 23% 4
Severe pain 14% 19% 19% 4
PHN
PHN proportion 13.1% 15.2% 18.0% 25
PHN pain duration 8.3 months 10.9 months 10.9 months 4,56
PHN pain split
No pain — — —
Mild pain 42% 17% 17% 4
Moderate pain 9% 16% 16% 4
Severe pain 49% 67% 67% 4
Vaccine efﬁcacy
Vaccine efﬁcacy (initial reduction of HZ incidence
after vaccination
66.7% 59.9% 51.6% 4,20
Vaccine efﬁcacy on PHN among HZ cases 5.0% 55.0% 55.0% 4,20
PHN duration with vaccine 8.07 months 9.58 months 9.58 months 4,56
PHN duration without vaccine 10.34 months 12.90 months 12.90 months 4,56
HZ: herpes zoster; PHN: indicates post-herpetic neuralgia, deﬁned as pain persisting or occurring after herpes zoster rash onset
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published data on efﬁcacy decline following vaccination vary
between 0% and 8.3% per year.21 Given that the waning rate is
not constant over time and unequal among different age
groups, data from a durability model were incorporated. The
durability model was developed to assess the efﬁcacy of HZ
vaccine based on long-term efﬁcacy data, the age at time of
vaccination and time since vaccination.21,30
The assumption was made that at 13 y, 18 y and 23 y after
vaccination the vaccine efﬁcacy would rebound to zero for the
75–79 y, 70–74 y and 65–69 y old individuals, respectively
(Appendix 2). Appendix 2 shows the assumed decline in efﬁ-
cacy over time for various age groups.21,30
Vaccine efﬁcacy duration on PHN. Due to the lack of statisti-
cally signiﬁcant data for PHN, the durability model could only
be estimated for efﬁcacy regarding HZ incidence. As a conse-
quence, the duration of protection from PHN was set to 10 y in
the base case, meaning that after 10 y with full efﬁcacy it would
rebound to zero.
Transition probabilities
HZ and PHN. The direct effects on occurrence of HZ were
applied to the transition probabilities (TP) “Healthy to HZ”
and “HZ to PHN“ as follows:
TP vaccinated populationð Þ
DTP non¡ vaccinated populationð Þ  1¡ efficacyð Þ
The indirect effect on PHN occurrence was included implic-
itly as this was an additional effect of the direct HZ effect.
PHN duration. The values for PHN durations, differing by age
( 69 and  70) and vaccination status, were included in the
model by adjusting the transition probabilities associated with
each of the 4 distinct 5-year age groups. Modeling PHN dura-
tion required transition probabilities resulting in PHN patients
remaining in PHN states for several cycles equal to the average
PHN duration (in months). The main assumption in calculat-
ing PHN pain state transition probabilities was that pain would
decrease over time and eventually cease.
PHN pain split. Calculating the transition probabilities
required a calibration exercise using a basic Markov chain. An
initial cohort with the Oxman et al. pain split was considered
during the ﬁrst cycle.4 A constant probability was assumed for
all PHN patients transitioning to the next lower pain state
(severe to moderate; moderate to mild; mild to full health).
A sufﬁcient number of cycles were calculated until nearly all
patients (> 99%) were no longer in pain. Finally, average dura-
tion of pain was calculated for this population. The initial, con-
stant probability was then adjusted until the average duration
of pain was equal to the PHN duration provided by Oxman
et al. The resulting constant probability was the PHN pain state
transition probability. This exercise was conducted 4 times, to
reﬂect the available information on PHN duration, which dif-
fered by age and vaccination status. The transition probabilities
included were 23.0% and 22.0% for the vaccination policy and
18.2% and 16.2% for the no-vaccination policy for the 60–69 y
old and  70 y old individuals, respectively.
Utilities
The model contains different pain states and speciﬁc utilities
associated with these states. The pain states related to HZ cover
no pain; mild pain; moderate pain; and severe pain. The pain
states related to PHN exclude the no-pain state, as pain is a
prerequisite for a PHN diagnosis.
The utilities of the various pain states were used to obtain
decrements which were subsequently applied to age-speciﬁc utili-
ties.7 Decrements were deﬁned as the part of the baseline utility
(i.e., HZ with no pain) that needed to be subtracted to obtain
the utility value for a given health state (Table 4). These were
combined with age-speciﬁc utilities for the general population.
UK data from the Health Survey for England were used for this
purpose, since no age-speciﬁc utility values by gender are avail-
able for the Swiss population (65–74 years: 0.92 male, 0.85
female; 75–79 years: 0.85 male, 0.80 female).57 Since non-gender-
separated 5-year age groups in the Swiss population were evalu-
ated at one time, overall utility values were calculated from this
data by weighting the male and female utility values by the gen-
der distribution in the relevant age groups in Switzerland.
The ﬁnal utility values were calculated as the age-speciﬁc utili-
ties minus the applicable decrement of the speciﬁc health state.
Additionally, alternative utility inputs were extracted from other
publications and assessed in sensitivity analyses21-23 (Table 2).
Table 4. Monthly costs and utilities of HZ and PHN management.
Monthly costs
(values for 2014)
Primary/outpatient
care costs
Non pharmacological
treatment Medications
Diagnostic
testing Hospitalization
Utility
decrement
HZ pain severity
No pain CHF 124.52 CHF 0.00 CHF 186.20 CHF 42.74
Mild pain CHF 124.52 CHF 0.00 CHF 186.77 CHF 52.24 CHF 0.00 0.201
Moderate pain CHF 124.52 CHF 0.00 CHF 201.20 CHF 52.24 CHF 0.00 0.329
Severe pain CHF 282.81 CHF 79.14 CHF 250.48 CHF 52.24 CHF 648.95 0.711
PHN pain severity
Mild pain CHF 114.41 CHF 0.00 CHF 8.24 CHF 1.58 CHF 0.00 0.201
Moderate pain CHF 114.41 CHF 92.34 CHF 14.55 CHF 1.58 CHF 72.11 0.329
Severe pain CHF 364.33 CHF 316.58 CHF 88.77 CHF 1.58 CHF 144.21 0.711
Source 26 26 26 26 26,59 7,57
No information could be identiﬁed for the common medication dose of drugs used for the therapy of HZ and PHN, and no data regarding the distribution of medication
costs with respect to age groups or pain split were available
HZ: herpes zoster; PHN: indicates post-herpetic neuralgia, deﬁned as pain persisting or occurring after herpes zoster rash onset
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Costs
Vaccine cost. Unit cost of vaccination to the third party payer
was estimated at CHF 162.00 (by subtracting a 10% co-pay-
ment of CHF 16.20). We assumed that 10% of administrations
occurred at the same time as the administration of a ﬂu vaccine;
thus administration costs were estimated at CHF 22.68 includ-
ing an inﬂation rate as used in the earlier publication.11
Management of HZ and PHN. Dataonhealthcareutilizationand
costs in themodelwere basedonaSwiss burdenof illness study con-
ducted in 200726. The study investigated the consumption of health
care-related resources associated with HZ and PHN and the cost of
currentHZ/PHNmanagement inSwisspatientsaged50yandolder.
The informationwas derived froman interviewwith 2 Swiss experts
witharecognizedexpertiseinHZandPHNdiseases.Allcostsparam-
etersprovidedbythisstudywereinﬂatedto2014costsusingtheSwiss
consumerpriceindex(Table 4).58
Hospitalization. The mean length of hospital stay and the
mean hospitalization cost during the acute and chronic phases
of severe HZ cases and moderate to severe PHN cases were esti-
mated using hospitalizations records from the University of
Vaud Hospital Centre (CHUV). Hospitalization records were
extracted when a HZ related ICD-10 (International classiﬁca-
tion of diseases, Version 10) was registered as main diagnosis
code between 2010 and 2013. In total, 78 hospitalizations were
extracted. From these hospitalizations a mean cost per day of
CHF 1,472 and a mean length of stay of 9.80 d were estimated
(CHF 14,421).26 The hospitalization costs were calculated as
monthly costs to match the Markov cycle length of one month.
For PHN, the hospitalization cost for patients with moderate
pain was CHF 72.11 and CHF 144.21 for patients with severe pain
(average hospitalization costs). For HZ, no hospitalization was
estimated for the patients with mild or moderate pain. For patient
with severe pain, the hospitalization was CHF 648.95 (Table 4).
Sensitivity-analysis
Deterministic sensitivity analyses
Deterministic sensitivity analyses (DSAs) were performed to
assess the impact of parameter uncertainty and alternative
assumptions on the model results. By changing one parameter
at a time and leaving all other parameters constant, possible
boundaries of the cost-effectiveness results were deﬁned and
parameters with a strong impact on the ICER were identiﬁed.
Variables subjected to variation included epidemiological
inputs (HZ and PHN incidence, HP pain split and HZ mortal-
ity), discount rates, descriptors of management of HZ care,
vaccine price, vaccine efﬁcacy, vaccine efﬁcacy duration and
utility values.
Probabilistic sensitivity analyses
Probabilistic sensitivity analyses (PSA) were conducted to
describe and account for the uncertainty surrounding input
parameters, jointly. The principle is to run the model a large
number of times (i.e., 1,000 runs), with different sets of inputs
drawn randomly from pre-speciﬁed distributions.
Parameters most inﬂuential in the DAS were included in the
PSA (health care resource costs, HZ/PHN utility values, HZ
incidence and PHN proportion). Table 5 shows all variables
included with their distributions and respective values.
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